Form 8-K - Current report:
SEC Accession No. 0001213900-24-113561
Filing Date
2024-12-30
Accepted
2024-12-30 17:28:13
Documents
21
Period of Report
2024-12-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0226258-8k_osthera.htm   iXBRL 8-K 53237
2 CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES AND LIMITATIONS OF SERIES A SE ea022625801ex3-1_osthera.htm EX-3.1 128218
3 FORM OF WARRANT ea022625801ex4-1_osthera.htm EX-4.1 110937
4 FORM OF AGENT WARRANT ea022625801ex4-2_osthera.htm EX-4.2 108388
5 SECURITIES PURCHASE AGREEMENT, DATED DECEMBER 24, 2024, BY AND AMONG OS THERAPIE ea022625801ex10-1_osthera.htm EX-10.1 273723
6 FORM OF REGISTRATION RIGHTS AGREEMENT ea022625801ex10-2_osthera.htm EX-10.2 128599
7 FORM OF VOTING AGREEMENT ea022625801ex10-3_osthera.htm EX-10.3 54511
8 LETTER AGREEMENT, DATED DECEMBER 27, 2024, BY AND BETWEEN OS THERAPIES INCORPORA ea022625801ex10-4_osthera.htm EX-10.4 235493
9 PRESS RELEASE, DATED DECEMBER 24, 2024 ea022625801ex99-1_osthera.htm EX-99.1 15842
  Complete submission text file 0001213900-24-113561.txt   1517883

Data Files

Seq Description Document Type Size
10 XBRL SCHEMA FILE ostx-20241224.xsd EX-101.SCH 3024
11 XBRL LABEL FILE ostx-20241224_lab.xml EX-101.LAB 34240
12 XBRL PRESENTATION FILE ostx-20241224_pre.xml EX-101.PRE 22365
23 EXTRACTED XBRL INSTANCE DOCUMENT ea0226258-8k_osthera_htm.xml XML 3924
Mailing Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850
Business Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850 410-297-7793
OS Therapies Inc (Filer) CIK: 0001795091 (see all company filings)

EIN.: 825118368 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42195 | Film No.: 241590664
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)